Lilly USA, LLC Launches New Rotation Program for Medical Students Tulane University School of Medicine participates in pilot program
INDIANAPOLIS, Feb. 12, 2014 /PRNewswire/ -- Lilly USA, LLC (NYSE: LLY) announced today the launch of a new rotation program for aspiring physicians. The rotation assignments cut across different aspects of the pharmaceutical company's business – from drug discovery and development to bioethics and patient safety – providing third- and fourth-year medical students a lens into the pharmaceutical industry, its vision and focus on improving patient outcomes.
Students from Tulane University School of Medicine will be the first to participate in the pilot program at Eli Lilly and Company's Indianapolis headquarters.
"We're excited to kick off the Medical Student Rotation Program," said Yolanda Johnson-Moton, director of external relations, US Medical Division, Lilly. "The students selected for this program distinguished themselves, both academically and during the interview process.
"The program is intensive and exposes these future practitioners to the various scientific and medical phases of the drug development process, along with a holistic view of the company. Students have a unique vantage point and opportunity to work alongside some of the most talented health care professionals in the industry, including physicians, and understand their important roles in our organization."
The Medical Student Rotation Program is a four-week experiential learning program. In partnership with Tulane University School of Medicine, medical students will gain experience and understanding of drug development and how physicians at Lilly contribute to the process. The program features a student-centric curriculum and structured mentorship in various aspects of pharmaceutical development. This includes independent projects, industry-led workshops, exposure to many facets of drug discovery and development and networking opportunities with Lilly medical leaders.
"Students participating in the program will get hands-on knowledge of the many roles physicians play in the pharmaceutical industry," said Dr. Marc J. Kahn, senior associate dean for admissions and student affairs at Tulane University School of Medicine. "The partnership between Lilly and Tulane matches Lilly's commitment to medical education with Tulane's passion for providing exciting educational experiences for our students. Tulane has the largest combined MD/MPH program in the country, a successful MD/MBA program and a program in medical innovation. This experience combined with Lilly's reputation as a leader in the pharmaceutical industry makes the partnership a natural one."
About Tulane University School of Medicine
One of the nation's most recognized centers for medical education, Tulane University School of Medicine is a vibrant center for education, research and public service. Tulane School of Medicine is the second-oldest medical school in the Deep South and the 15th oldest medical school in the United States. Tulane School of Medicine recruits top faculty, researchers and students from around the world, and pushes the boundaries of medicine with groundbreaking medical research and surgical advances. Tulane remains in the forefront of modern medical innovation and is equipping the next generation of medical professionals with the tools to succeed in the rapidly changing future of health care.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. P-LLY
SOURCE Eli Lilly and Company